8-K: enGene Holdings Announces Positive Preliminary Data for Bladder Cancer Treatment Detalimogene

enGene Holdings reported promising preliminary data from its LEGEND study, showing a 71% complete response rate at any time for its bladder cancer treatment, detalimogene.

Summary

• enGene Holdings announced preliminary data from the ongoing pivotal cohort of the LEGEND study for detalimogene, a treatment for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis).
• The study assessed 21 patients at three months and 17 of those patients at six months, with a data cutoff date of September 13, 2024.
• The results showed a 71% complete response (CR) rate at any time, a 67% CR rate at three months, and a 47% CR rate at six months.
• Using Kaplan-Meier analysis, the estimated complete response rate at six months was 51%.
• The treatment was generally well-tolerated, with no discontinuations due to treatment-related adverse events (TRAEs).
• Out of 42 patients in the safety analysis, 47.6% experienced any grade TRAE, with most being Grade 1 or 2, and only two Grade 3 TRAEs reported.
• The most common TRAEs were dysuria, bladder spasm, pollakiuria, and fatigue.

Sentiment

Score: 8

Explanation: The document presents very positive preliminary clinical data with a high complete response rate and good tolerability, suggesting a promising outlook for the treatment. The sentiment is very positive.

Positives

• Detalimogene demonstrated a high complete response rate, with 71% of patients achieving a response at any time.
• The treatment showed a favorable tolerability profile, with no drug-related discontinuations.
• The data is consistent with Phase 1 results, increasing confidence in the treatment's profile.
• Detalimogene has convenient attributes, including ease of handling, administration, minimal storage requirements, and lack of post-procedural patient restrictions.
• The treatment has the potential to be a broadly utilized option for NMIBC patients, especially in community practice settings.

Negatives

• Some patients experienced treatment-related adverse events, although most were mild to moderate (Grade 1 or 2).
• Two patients experienced Grade 3 TRAEs, including peripheral edema and urosepsis.

Risks

• Preliminary clinical data may not accurately reflect the complete results of the study and are subject to audit and verification.
• Final data may differ materially from preliminary data.
• The company faces risks related to recruiting and retaining qualified personnel, establishing clinical trial sites, and enrolling patients.
• There are risks associated with executing clinical development plans and securing regulatory approval on anticipated timelines.

Future Outlook

The company plans to initiate enrollment of three additional cohorts in the LEGEND study in the fourth quarter of 2024 and remains on track to file a Biologics License Application (BLA) for detalimogene in mid-2026.

Management Comments

• Raj Pruthi, M.D., Chief Medical Officer of enGene, stated that the data clearly demonstrates that detalimogene is highly active and generally well tolerated.
• Suzanne Merrill, M.D., a urologist, remarked that the data combined with detalimogene's ease of use underscores its potential to become a broadly utilized treatment option.
• Ron Cooper, Chief Executive Officer of enGene, said that detalimogene was designed to be the most practical therapy for urologists to manage NMIBC.

Industry Context

This announcement is significant as it provides promising data for a new treatment option for NMIBC, a disease with high clinical burden and treatment costs. The positive results could position enGene as a key player in the bladder cancer treatment market.

Comparison to Industry Standards

• The 71% complete response rate at any time is a strong result compared to existing treatments for BCG-unresponsive NMIBC, which often have lower response rates.
• Current standard treatments such as radical cystectomy have significant side effects and are not suitable for all patients, making a well-tolerated treatment like detalimogene a potentially valuable alternative.
• Other companies such as CG Oncology and Ferring Pharmaceuticals are also developing treatments for NMIBC, but detalimogene's non-viral approach and ease of use could provide a competitive advantage.
• The lack of drug-related discontinuations in the study is a positive sign compared to some other treatments that may have higher rates of adverse events leading to treatment cessation.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data, potentially increasing the company's stock value.
• Patients with NMIBC may benefit from a new, effective, and well-tolerated treatment option.
• Urologists may find detalimogene to be a practical and convenient treatment option for their patients.
• Employees may be motivated by the positive results and the potential for the company's success.

Next Steps

• The company plans to initiate enrollment of three additional cohorts in the LEGEND study in the fourth quarter of 2024.
• The company is planning protocol refinements in LEGEND to provide patients with additional clinical benefit.
• The company remains on track to file a Biologics License Application (BLA) for detalimogene in mid-2026.

Key Dates

Keywords

detalimogene, bladder cancer, NMIBC, LEGEND study, complete response, BCG-unresponsive, carcinoma in situ, genetic medicine, clinical trial, oncology